Tatva Chintan Pharma Chem Ltd (TATVA) Q4FY26 Management Mirror - Mar-2026 Qtr
Revenue Outlook
Management expects approximately 25% revenue growth for the fiscal year ending Mar'27 (Mar'26 Qtr), consistent with the 20% to 30% range guided in the Dec'25 Qtr. Peak revenue potential from existing infrastructure remains targeted at INR 850 crores to INR 900 crores achievable by Mar'28, unchanged since the Dec'25 Qtr. [Status: Reaffirmed]
5 more themes on the ELITE plan.